Sorrento Therapeutics, Inc.

358 articles with Sorrento Therapeutics, Inc.

• Sorrento Therapeutics, Inc. Receives Final Court Approval for $75 Million Debtor-In-Possession Financing

  3/29/2023

  Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento") today announced that the U.S. Bankruptcy Court for the Southern District of Texas granted final approval of Sorrento's $75 million debtor-in-possession (DIP) financing from JMB Capital Partners, in connection with Sorrento's chapter 11 case that was filed on February 13, 2023.

• Scilex Holding Company and CH Trading Group Announce Territory Distribution Agreement to Expand Commercialization of ZTlido® for the Middle East and North Africa (MENA) With $105 Million Minimum Multi-Year Purchase Commitment

  3/8/2023

  Scilex Holding Company announced territory distribution agreement for ZTlido® in the Middle East and North Africa with $105 million minimum purchase commitment over 5 years.

• Scilex Holding Company announces the commercial launch of ELYXYBTM (celecoxib oral solution) in the U.S., strengthening its leadership position in non-opioid pain management

  2/27/2023

  Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the commercial launch of ELYXYBTM (celecoxib oral solution) in the U.S.

• Sorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 Case

  2/21/2023

  Sorrento Therapeutics, Inc. announced that the U.S. Bankruptcy Court for the Southern District of Texas granted interim approval of Sorrento's $75 million debtor-in-possession financing from JMB Capital Partners, in connection with Sorrento's chapter 11 case, which was filed on February 13, 2023.

• Sorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)

  2/19/2023

  Sorrento Therapeutics, Inc. posted an IRS Form 8937 to supplement its previously issued “Frequently Asked Questions” document under the “Investors” section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company previously held by Sorrento.

• Sorrento Issues Update to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)

  2/17/2023

  Sorrento Therapeutics, Inc. posted an update to its previously issued “Frequently Asked Questions” document under the “Investors” section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company previously held by Sorrento.

• Sorrento Therapeutics, Inc. Receives Court Approval for "First Day" Employee Wages and Cash Management Motions

  2/16/2023

  Sorrento Therapeutics, Inc. announced that the U.S. Bankruptcy Court for the Southern District of Texas granted approval of Sorrento's employee wages motion and interim approval of its cash management motion, in connection with Sorrento's chapter 11 petition, which was filed on February 13, 2023.

• Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today’s Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.

  2/13/2023

  Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. and an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, together with Sorrento, issued the following statements:.

• Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB™ in the U.S. and Canada for the acute treatment of migraine

  2/12/2023

  Scilex Holding Company announced that it has acquired rights to ELYXYBTM in the U.S. and Canada, the only FDA-approved ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.

• Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of Stockholders

  2/5/2023

  Scilex Holding Company announced that its first virtual-only Annual Meeting of Stockholders is scheduled to be held on April 6, 2023 at 9AM PST.

• Sorrento Distributes Dividend Confirmation Statements to 146 Brokerage Firms and Provides Specific Instruction to Continental Stock Transfer & Trust Company Regarding the Dividend of Scilex Holding Company Common Stock

  2/4/2023

  Sorrento Therapeutics, Inc. distributed dividend confirmation statements to 146 brokerage firms regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento.

• Sorrento Therapeutics has Received FDA Clearance to Initiate Clinical Trials with a Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus

  12/6/2022

  Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") has received clearance from the US FDA to initiate clinical trials with STI-1557, its next generation mRNA vaccine against SARS-CoV-2 Omicron variants.

• Sorrento Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology (ESMO)

  12/5/2022

  Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) is pleased to announce the results of a Phase II NK/T-cell lymphoma study of IMC-001, a PD-L1 monoclonal antibody licensed to ImmuneOncia Therapeutics, LLC (“ImmuneOncia”) (Seongnam, South Korea). ImmuneOncia is a biotechnology company specializing in immuno-oncology drug development, jointly established by Yuhan Corporation of Korea and Sorrento.

• Sorrento to Host Webcast to Discuss Newly Presented Clinical Data Demonstrating Significant Improvements in Therapeutic Outcomes in 10 of 10 Patients with Poorly Controlled Rheumatoid Arthritis

  11/13/2022

  Sofusa®, a wholly-owned division of Sorrento Therapeutics, announced that it will host a virtual Key Opinion Leader panel discussion titled “Empowering the Lymphatics: Unleashing the Potential of Biologics that Target the Immune System” to be held on Thursday, November 17, 2022 at 11:30 AM EST.

• Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), Debuts on Nasdaq Under Ticker “SCLX”

  11/10/2022

  Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that shares of its common stock will trade on the Nasdaq Capital Market on Friday, November 11, 2022 under the ticker symbol “SCLX”.

• Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Announce the Closing of their Previously Announced Business Combination

  11/10/2022

  Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and Vickers Vantage Corp.

• Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study for Sorrento Therapeutics, Inc. with Results To Be Presented at the 2022 American College of Rheumatology Conference

  10/26/2022

  Nutriband Inc today announced that its subsidiary, 4P Therapeutics LLC has conducted a Phase 1b clinical study for Sorrento Therapeutics, Inc.

• Sorrento Successfully Completes Phase 1 Study and Is Proceeding to Implement Global Registrational Trials with STI-1558, an Oral Mpro Inhibitor as a Standalone Oral Treatment and Prevention of COVID-19 without the Need for a Ritonavir Booster

  10/17/2022

  Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the completion of a Phase 1 study of its oral main viral protease (Mpro) inhibitor, the STI-1558 in 58 healthy volunteers.

• Sorrento Announces Publication of Data in Cell Press Journal Med Describing Discovery and Preclinical Efficacy of a Broadly-Acting SARS-CoV-2 Neutralizing Antibody Administered IV (STI-9167) or IN (STI-9199)

  10/14/2022

  Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced publication in the Cell Press journal Med of data detailing work relating to the discovery and preclinical profiling of STI-9167 neutralizing antibody activity against a broad collection of SARS-CoV-2 variants, including select Omicron subvariants.

• Sorrento Therapeutics to Participate in Key Opinion Leader Panel Discussion on “New Horizons for the Treatment of Non-small Cell Lung Cancer”

  10/6/2022

  Sorrento Therapeutics, Inc. announced that Dr. Mike A. Royal, Chief Medical Officer, will participate in an upcoming Key Opinion Leader Panel Discussion that will focus on the great unmet need in non-small cell lung cancer and the potential of abivertinib, a novel, third-generation, EGFR/BTK inhibitor.